USANA Health Sciences (NYSE:USNA) Rating Lowered to C+ at TheStreet

USANA Health Sciences (NYSE:USNA) was downgraded by research analysts at TheStreet from a “b+” rating to a “c+” rating in a research note issued to investors on Tuesday, February 6th.

A number of other analysts also recently weighed in on USNA. Pivotal Research upped their target price on shares of USANA Health Sciences from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. BidaskClub raised shares of USANA Health Sciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, Sidoti downgraded shares of USANA Health Sciences from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 24th.

Shares of USANA Health Sciences (USNA) traded up $0.20 during trading on Tuesday, reaching $75.95. 6,514 shares of the company’s stock were exchanged, compared to its average volume of 89,970. The stock has a market cap of $1,812.64, a P/E ratio of 30.06 and a beta of 0.99. USANA Health Sciences has a fifty-two week low of $52.55 and a fifty-two week high of $79.00.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.00 by $0.11. The business had revenue of $273.11 million for the quarter, compared to the consensus estimate of $258.67 million. USANA Health Sciences had a net margin of 5.97% and a return on equity of 27.02%. The company’s quarterly revenue was up 8.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.87 EPS. analysts predict that USANA Health Sciences will post 4.25 earnings per share for the current fiscal year.

In other news, Director Myron W. Wentz sold 7,895 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $66.03, for a total value of $521,306.85. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Myron W. Wentz sold 28,405 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $75.39, for a total transaction of $2,141,452.95. The disclosure for this sale can be found here. Insiders have sold a total of 347,774 shares of company stock worth $23,709,986 in the last 90 days. Company insiders own 53.20% of the company’s stock.

Several large investors have recently modified their holdings of USNA. Renaissance Technologies LLC raised its stake in USANA Health Sciences by 0.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,930,966 shares of the company’s stock worth $142,988,000 after acquiring an additional 12,700 shares during the period. Vanguard Group Inc. raised its stake in USANA Health Sciences by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 979,726 shares of the company’s stock worth $62,801,000 after acquiring an additional 25,136 shares during the period. Dimensional Fund Advisors LP raised its stake in USANA Health Sciences by 5.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 751,018 shares of the company’s stock worth $43,334,000 after acquiring an additional 40,100 shares during the period. BlackRock Inc. raised its stake in USANA Health Sciences by 0.4% during the 4th quarter. BlackRock Inc. now owns 725,965 shares of the company’s stock worth $53,758,000 after acquiring an additional 3,161 shares during the period. Finally, Nordea Investment Management AB raised its stake in USANA Health Sciences by 2.6% during the 3rd quarter. Nordea Investment Management AB now owns 344,217 shares of the company’s stock worth $19,861,000 after acquiring an additional 8,768 shares during the period. Hedge funds and other institutional investors own 44.67% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://weekherald.com/2018/02/15/usana-health-sciences-usna-downgraded-by-thestreet.html.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply